Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase1, First-in-Human, Open-Label, Dose Escalation and Expansion Study of CUE-101 Monotherapy in Second Line or CUE-101 Combination Therapy With Pembrolizumab in First Line Patients With HPV16+ Recurrent/Metastatic HNSCC

NCT03978689 is registered in ClinicalTrials.gov with Cue Biopharma as lead sponsor.

NCT NCT03978689
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03978689 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase1, First-in-Human, Open-Label, Dose Escalation and Expansion Study of CUE-101 Monotherapy in Second Line or CUE-101 Combination Therapy With Pembrolizumab in First Line Patients With HPV16+ Recurrent/Metastatic HNSCC
Lead sponsor
Cue Biopharma
Phase
Phase 1
Overall status
Completed
Start date
July 30, 2019
Completion date
January 4, 2026
Enrollment
80 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck cancer, hpv positive oropharyngeal squamous cell carcinoma, hpv-related carcinoma